Study Agents
|
Other agents
|
Disease
|
Dosage
|
Clinical trails
|
No Pts
|
Response
|
Reference
|
---|
Vorinostat
|
Idarubicin, Cytarabine
|
untreated AML
|
500 mg po tid d1-3
|
Phase II
|
52
|
CR/CRp: 80%
|
[37]
|
Vorinostat
|
decitabine
|
untreated, relapsed AML
|
400 mg qd, po 1-7d or 1-14d
|
Phase I/II
|
72
|
MTD not reached
|
[38]
|
- Abbreviations: CR: complete remission; CRp: CR without platelet recovery; MTD: maximal tolerated dose;